Frontiers in pediatrics · 2026
Clinical outcomes and adverse events associated with intravenous polymyxin-containing therapy in hospitalized children with resistant Gram-negative infections: a systematic review and meta-analysis.
СтатьяСистематический обзорНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Chen Huilian, Ali Mure, Huang Hongyuan, Ning Junjie, Luo Shuanghong, Qiao Lina
Аннотация
BACKGROUND: Intravenous polymyxins remain salvage agents for resistant Gram-negative infections in children, but pediatric evidence on clinical outcomes and toxicity is fragmented.
METHODS: We systematically searched PubMed, Embase, Web of Science, the Cochrane Library, CNKI, Wanfang Data, SinoMed, and VIP from inception to 31 January 2025. Eligible studies reported intravenous polymyxin-containing therapy in hospitalized pediatric patients with documented or suspected resistant Gram-negative infections. Random-effects single-arm meta-analyses were used to estimate pooled outcome proportions.
RESULTS: Twenty-four studies comprising 1,152 reported patients or treatment units were included, most of which were single-arm observational studies. The pooled proportions were 22% [95% confidence interval (CI) 16%-27%] for all-cause mortality, 14% (95% CI 11%-17%) for infection-related mortality, 65% (95% CI 58%-72%) for clinical improvement, 13% (95% CI 9%-17%) for overall adverse events, and 10% (95% CI 7%-14%) for nephrotoxicity. Neurotoxicity and hepatotoxicity were infrequently reported. Clinical setting, dosing, outcome definitions, and units of analysis were heterogeneous.
CONCLUSIONS: The available evidence describes outcomes observed during intravenous polymyxin-containing therapy in hospitalized children but does not establish comparative efficacy or causality for adverse events. Prospective multicenter pediatric studies using standardized dosing, outcome, and safety definitions are needed.
METHODS: We systematically searched PubMed, Embase, Web of Science, the Cochrane Library, CNKI, Wanfang Data, SinoMed, and VIP from inception to 31 January 2025. Eligible studies reported intravenous polymyxin-containing therapy in hospitalized pediatric patients with documented or suspected resistant Gram-negative infections. Random-effects single-arm meta-analyses were used to estimate pooled outcome proportions.
RESULTS: Twenty-four studies comprising 1,152 reported patients or treatment units were included, most of which were single-arm observational studies. The pooled proportions were 22% [95% confidence interval (CI) 16%-27%] for all-cause mortality, 14% (95% CI 11%-17%) for infection-related mortality, 65% (95% CI 58%-72%) for clinical improvement, 13% (95% CI 9%-17%) for overall adverse events, and 10% (95% CI 7%-14%) for nephrotoxicity. Neurotoxicity and hepatotoxicity were infrequently reported. Clinical setting, dosing, outcome definitions, and units of analysis were heterogeneous.
CONCLUSIONS: The available evidence describes outcomes observed during intravenous polymyxin-containing therapy in hospitalized children but does not establish comparative efficacy or causality for adverse events. Prospective multicenter pediatric studies using standardized dosing, outcome, and safety definitions are needed.